DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Discover Key Insights into the Dravet Syndrome Market with DelveInsight’s In-Depth Report @ Dravet Syndrome Market Size

 

Key Takeaways from the Dravet Syndrome Market Report

• In November 2024:- UCB BIOSCIENCES, Inc.- Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome. The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.
• In November 2024:- Zogenix Inc.- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension.
• According to NORD (2018), Dravet Syndrome affects an estimated 1:15,700 individuals in the US, or 0.0064% of the population. Approximately 80-90% of those, or 1:20,900 individuals, have both an SCN1A mutation and a clinical diagnosis of DS. This represents an estimated 0.17% of all epilepsies
• According to Dravet Syndrome Foundation (2022), a recent US epidemiology study concluded that Dravet Syndrome is twice as common as previously recognized, affecting 1:15,700 infants, 80% of whom have an SCN1A mutation.
• As per the study by Gil-Nagel et al. (2019), the average incidence rate among pediatric and adult patients is 1.1 cases and 0.5 cases per million inhabitants, respectively in Spain.
• In the UK, the total number of treated Dravet Syndrome cases ave been estimated at around 1,000 cases in 2022.
• In the US, the total incident Dravet Syndrome cases have been estimated at around 21,760 cases in 2022.
• In France, the total diagnosed Dravet Syndrome cases have been estimated at around 1,050 cases in 2022.
• In Japan, the total incident Dravet Syndrome cases have been estimated around 2,800 cases in 2022.
• The leading Dravet Syndrome Companies such as Biocodex, GW Pharmaceuticals, Zogenix, Ovid Therapeutics, PTC Therapeutics, and others.
• Promising Dravet Syndrome Therapies such as Ganaxolone, ETX101, fenfluramine, ETX101, LP352, and others.

 

Stay ahead in the Dravet Syndrome Therapeutics Market with DelveInsight’s Strategic Report @ Dravet Syndrome Market Outlook

 

Dravet Syndrome Epidemiology Segmentation in the 7MM

• Total Incident Cases of Dravet Syndrome
• Total Diagnosed Cases of Dravet Syndrome
• Mutation-Specific Incident Cases of Dravet Syndrome
• Age-specific Incident Cases of Dravet Syndrome
• Gender-specific Incident Cases of Dravet Syndrome
• Total Treated Cases of Dravet Syndrome

 

Download the report to understand which factors are driving Dravet Syndrome epidemiology trends @ Dravet Syndrome Prevalence

 

Dravet Syndrome Market Insights

Dravet Syndrome is a devastating disorder characterized by intractable epilepsy and poor neurodevelopmental outcome. It is a spectrum disorder patients present with a wide range of severity and seizure types, and no two patients respond to treatment the same way. Although there is no cure for Dravet syndrome, most treatments aim to reduce seizures. What helps one may not help another. Some medications have proven beneficial in many patients (sometimes called “first line treatments”) and some medications have been known to exacerbate seizures in many patients (called “contraindicated” medications) due to their effects on the sodium ion channel.

 

Dravet Syndrome Drug Market

According to DelveInsight’s analysis, the market for Dravet Syndrome is anticipated to increase during the forecast period (2024–2034), owing to launch of emerging therapies and healthcare spending globally.

 

Get In-Depth Knowledge on Dravet Syndrome Market Trends and Forecasts with DelveInsight @ Dravet Syndrome Treatment Market

 

Dravet Syndrome Drugs Uptake

• STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities.
• Encoded is developing ETX101, a potential one-time, disease-modifying gene regulation therapy for SCN1A+ Dravet syndrome. ETX101, Encoded’s lead program, is specifically designed to address the underlying cause of Dravet syndrome, the most common developmental and epileptic encephalopathy. ETX101 is a cell-selective gene therapy in development to potentially address the full range of seizure, cognitive, behavioral, developmental and motor manifestations of Dravet syndrome.

 

Dravet Syndrome Market Dynamics

The Dravet Syndrome market dynamics is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options.

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Dravet Syndrome Market Report @ Dravet Syndrome Market Drivers and Barriers

 

Scope of the Dravet Syndrome Market Report

• Coverage- 7MM
• Dravet Syndrome Companies- Biocodex, GW Pharmaceuticals, Zogenix, Ovid Therapeutics, PTC Therapeutics, Takeda, Epygenix Therapeutics, Stoke Therapeutics, Longboard Pharmaceuticals, Encoded Therapeutics, Eisai, Virpax Pharmaceuticals, and others.
• Dravet Syndrome Therapies- EPX-100 (Clemizole HCl), Soticlestat, ZX008 (Fenfluramine Hydrochloride), Cannabidiol, LP352, bexicaserin, and others.
• Dravet Syndrome Market Dynamics: Dravet Syndrome Market drivers and Dravet Syndrome Market Barriers
• Dravet Syndrome Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Dravet Syndrome Unmet Needs, KOL’s views, Analyst’s views, Dravet Syndrome Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Executive Summary of Dravet Syndrome

3. Competitive Intelligence Analysis for Dravet Syndrome

4. Dravet Syndrome: Market Overview at a Glance

5. Dravet Syndrome: Disease Background and Overview

6. Patient Journey

7. Dravet Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Dravet Syndrome Unmet Needs

10. Key Endpoints of Dravet Syndrome Treatment

11. Dravet Syndrome Marketed Products

12. Dravet Syndrome Emerging Therapies

13. Dravet Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Dravet Syndrome

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity